$9.56
Live
1.05%
Downside
Day's Volatility :4.64%
Upside
3.63%
56.8%
Downside
52 Weeks Volatility :61.18%
Upside
10.15%
Period | Inogen Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 43.07% | 6.5% | 0.0% |
6 Months | 70.18% | 7.1% | 0.0% |
1 Year | 16.73% | 9.8% | 0.0% |
3 Years | -86.69% | 14.2% | -20.2% |
Market Capitalization | 221.6M |
Book Value | $8.15 |
Earnings Per Share (EPS) | -4.16 |
PEG Ratio | 3.48 |
Wall Street Target Price | 7.0 |
Profit Margin | -30.07% |
Operating Margin TTM | -19.82% |
Return On Assets TTM | -10.65% |
Return On Equity TTM | -40.86% |
Revenue TTM | 321.5M |
Revenue Per Share TTM | 13.82 |
Quarterly Revenue Growth YOY | 8.1% |
Gross Profit TTM | 153.5M |
EBITDA | -40.4M |
Diluted Eps TTM | -4.16 |
Quarterly Earnings Growth YOY | 0.87 |
EPS Estimate Current Year | -2.21 |
EPS Estimate Next Year | -1.93 |
EPS Estimate Current Quarter | -0.76 |
EPS Estimate Next Quarter | -0.6 |
What analysts predicted
Downside of 26.78%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 358.1M | ↑ 43.57% |
Net Income | 51.8M | ↑ 146.86% |
Net Profit Margin | 14.48% | ↑ 6.06% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 361.9M | ↑ 1.07% |
Net Income | 21.0M | ↓ 59.59% |
Net Profit Margin | 5.79% | ↓ 8.69% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 308.5M | ↓ 14.77% |
Net Income | -5.8M | ↓ 127.82% |
Net Profit Margin | -1.89% | ↓ 7.68% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 358.0M | ↑ 16.05% |
Net Income | -6.3M | ↑ 8.65% |
Net Profit Margin | -1.77% | ↑ 0.12% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 377.2M | ↑ 5.37% |
Net Income | -83.8M | ↑ 1222.79% |
Net Profit Margin | -22.21% | ↓ 20.44% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 315.7M | ↓ 16.32% |
Net Income | -102.4M | ↑ 22.3% |
Net Profit Margin | -32.46% | ↓ 10.25% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 88.1M | ↓ 16.41% |
Net Income | -56.6M | ↑ 495.52% |
Net Profit Margin | -64.26% | ↓ 55.24% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 72.2M | ↓ 18.08% |
Net Income | -20.3M | ↓ 64.05% |
Net Profit Margin | -28.2% | ↑ 36.06% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 83.6M | ↑ 15.9% |
Net Income | -9.8M | ↓ 51.71% |
Net Profit Margin | -11.75% | ↑ 16.45% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 84.0M | ↑ 0.4% |
Net Income | -45.7M | ↑ 365.29% |
Net Profit Margin | -54.45% | ↓ 42.7% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 75.9M | ↓ 9.61% |
Net Income | -26.6M | ↓ 41.92% |
Net Profit Margin | -34.99% | ↑ 19.46% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 78.0M | ↑ 2.81% |
Net Income | -14.6M | ↓ 45.1% |
Net Profit Margin | -18.68% | ↑ 16.31% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 375.9M | ↑ 36.65% |
Total Liabilities | 65.5M | ↑ 36.32% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 447.3M | ↑ 19.01% |
Total Liabilities | 102.7M | ↑ 56.88% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 461.9M | ↑ 3.24% |
Total Liabilities | 112.2M | ↑ 9.26% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 489.5M | ↑ 5.99% |
Total Liabilities | 119.3M | ↑ 6.29% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 405.0M | ↓ 17.26% |
Total Liabilities | 107.6M | ↓ 9.77% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 326.2M | ↓ 19.47% |
Total Liabilities | 121.4M | ↑ 12.77% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 405.0M | ↓ 13.74% |
Total Liabilities | 107.6M | ↓ 9.35% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 385.7M | ↓ 4.78% |
Total Liabilities | 104.4M | ↓ 3.03% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 374.4M | ↓ 2.94% |
Total Liabilities | 99.6M | ↓ 4.6% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 343.7M | ↓ 8.19% |
Total Liabilities | 113.1M | ↑ 13.55% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 326.2M | ↓ 5.09% |
Total Liabilities | 121.4M | ↑ 7.35% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 315.6M | ↓ 3.25% |
Total Liabilities | 123.7M | ↑ 1.91% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 60.0M | ↓ 0.85% |
Investing Cash Flow | -25.0M | ↑ 2.19% |
Financing Cash Flow | 18.3M | ↑ 30.65% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 40.6M | ↓ 32.32% |
Investing Cash Flow | -44.1M | ↑ 76.48% |
Financing Cash Flow | 4.9M | ↓ 73.06% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 37.0M | ↓ 8.82% |
Investing Cash Flow | -25.6M | ↓ 41.8% |
Financing Cash Flow | 2.1M | ↓ 58.08% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 23.6M | ↓ 36.15% |
Investing Cash Flow | -14.6M | ↓ 42.88% |
Financing Cash Flow | 15.0M | ↑ 626.04% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -37.5M | ↓ 258.81% |
Investing Cash Flow | -10.9M | ↓ 25.73% |
Financing Cash Flow | 380.0K | ↓ 97.47% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -15.5M | ↑ 63.26% |
Investing Cash Flow | -6.9M | ↑ 46.04% |
Financing Cash Flow | -112.0K | ↓ 115.98% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -6.3M | ↓ 59.3% |
Investing Cash Flow | -17.1M | ↑ 146.4% |
Financing Cash Flow | 559.0K | ↓ 599.11% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 4.0M | ↓ 163.96% |
Investing Cash Flow | -540.0K | ↓ 96.84% |
Financing Cash Flow | -33.0K | ↓ 105.9% |
Sell
Neutral
Buy
Inogen Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Inogen Inc | 24.84% | 70.18% | 16.73% | -86.69% | -84.19% |
![]() Stryker Corporation | -3.84% | 5.16% | 12.86% | 24.25% | 52.69% |
![]() Boston Scientific Corp. | -3.68% | 21.48% | 41.72% | 68.89% | 76.47% |
![]() Edwards Lifesciences Corp. | -34.8% | -18.49% | -34.85% | -45.17% | -15.86% |
![]() Abbott Laboratories | 1.03% | -5.4% | -7.12% | -11.35% | 20.75% |
![]() Medtronic Plc | -1.99% | -9.34% | -13.21% | -38.74% | -23.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Inogen Inc | NA | NA | 3.48 | -2.21 | -0.41 | -0.11 | NA | 8.15 |
![]() Stryker Corporation | 38.91 | 38.91 | 2.92 | 11.95 | 0.19 | 0.07 | 0.01 | 50.33 |
![]() Boston Scientific Corp. | 63.22 | 63.22 | 1.8 | 2.37 | 0.09 | 0.05 | NA | 13.16 |
![]() Edwards Lifesciences Corp. | 36.4 | 36.4 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 33.84 | 33.84 | 5.99 | 4.66 | 0.15 | 0.06 | 0.02 | 22.31 |
![]() Medtronic Plc | 28.97 | 28.97 | 1.52 | 5.2 | 0.07 | 0.04 | 0.04 | 38.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Inogen Inc | Sell | $221.6M | -84.19% | NA | -30.07% |
![]() Stryker Corporation | Buy | $129.7B | 52.69% | 38.91 | 16.03% |
![]() Boston Scientific Corp. | Buy | $114.3B | 76.47% | 63.22 | 12.05% |
![]() Edwards Lifesciences Corp. | Buy | $52.4B | -15.86% | 36.4 | 23.74% |
![]() Abbott Laboratories | Buy | $186.6B | 20.75% | 33.84 | 13.65% |
![]() Medtronic Plc | Buy | $102.5B | -23.49% | 28.97 | 11.36% |
Insights on Inogen Inc
Revenue is up for the last 2 quarters, 75.89M → 78.02M (in $), with an average increase of 2.7% per quarter
Netprofit is up for the last 3 quarters, -45.71M → -14.57M (in $), with an average increase of 77.2% per quarter
In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 25.0%
In the last 3 years, Boston Scientific Corp. has given 68.9% return, outperforming this stock by 155.6%
Camber Capital Management LLC
Brown Capital Management, LLC
BlackRock Inc
Vanguard Group Inc
Morgan Stanley - Brokerage Accounts
JPMorgan Chase & Co
inogen’s mission to improve the quality of life of supplemental oxygen users began in 2001 when mae, a beloved grandmother, was prescribed oxygen therapy. learn more about mae’s story here: http://www.inogen.com/about-inogen/meet-mae/. inogen was founded based on our conviction that oxygen therapy technology was not keeping pace with the desired lifestyles of patients who depended on it to live longer, more fulfilling lives. we estimate that more than 2.5 million patients in the united states and more than 4.5 million patients worldwide use oxygen therapy. our compact, lightweight and travel-approved portable oxygen concentrators are designed to free patients from heavy tanks, managing tank refills or being tethered to stationary systems. we believe our products allow oxygen therapy patients to reclaim their freedom and independence so that life can be lived in moments, not in minutes left in an oxygen tank. with each step we take to improve our products and service, our customers take
Organization | Inogen Inc |
Employees | 834 |
CEO | Mr. Jason Somer |
Industry | Health Technology |
A Spac I Acquisition Corp
$9.56
-1.44%
Keyarch Acquisition Corp
$9.56
-1.44%
Connexa Sports Technologies Inc
$9.56
-1.44%
Us Value Etf
$9.56
-1.44%
First Wave Biopharma Inc
$9.56
-1.44%
Global X Msci Next Emerging
$9.56
-1.44%
Fat Projects Acquisition Corp
$9.56
-1.44%
Capital Link Global Fintech
$9.56
-1.44%
Applied Uv Inc
$9.56
-1.44%